Table 2.
Proportion of vaccinated patients on dialysis without RBD IgG^ over time
| Days 14-30 N=1369 |
Days 31-60 N=2304 |
Days 61-90 N=2292 |
Days 91-120 N=1861 |
Days 121-150 N=1228 |
Days 151-180 N=555 |
|
|---|---|---|---|---|---|---|
| RBD antibody status prior to vaccination | ||||||
|
| ||||||
| Negative, n | 912 | 1601 | 1589 | 1346 | 974 | 503 |
| % without RBD IgG | 7.1 (5.6, 9.0) | 8.1 (6.9, 9.6) | 9.3 (8.0, 10.9) | 11.7 (10.1, 13.6) | 17.0 (14.8, 19.6) | 20.5 (17.2, 24.3) |
| Positive, n | 457 | 703 | 703 | 515 | 254 | 52 |
| % without RBD IgG | 5.7 (3.9, 8.3) | 6.0 (4.5, 8.0) | 6.7 (5.1, 8.8) | 8.7 (6.6, 11.6) | 14.2 (10.5, 19.2) | 17.3 (9.6, 31.4) |
|
| ||||||
| Vaccine type | ||||||
|
| ||||||
| mRNA1273, n | 605 | 1116 | 1105 | 1072 | 713 | 321 |
| % without RBD IgG | 2.3 (1.4, 3.9) | 3.0 (2.2, 4.2) | 4.5 (3.5, 5.9) | 5.5 (4.3, 7.1) | 8.6 (6.7, 10.9) | 10.9 (8.0, 14.9) |
| BNT162b2 | 720 | 1033 | 1094 | 696 | 436 | 230 |
| % without RBD IgG | 6.3 (4.7, 8.3) | 8.0 (6.5, 9.9) | 9.3 (7.8, 11.2) | 13.6 (11.3, 16.5) | 22.0 (18.5, 26.3) | 31.7 (26.3, 38.4) |
| Ad26.COV2.S | 44 | 105 | 93 | 93 | 79 | |
| % without RBD IgG | 72.7 (60.7, 87.2) | 51.4 (42.7, 61.9) | 46.2 (37.1, 57.6) | 52.7 (43.5, 63.9) | 57.0 (47.0, 69.0) | |
|
| ||||||
| RBD antibody status prior to vaccination | ||||||
|
| ||||||
| Negative | ||||||
| mRNA1273, n | 409 | 823 | 786 | 773 | 568 | 288 |
| % without RBD IgG | 2.7 (1.5, 4.8) | 3.5 (2.5, 5.0) | 5.5 (4.1, 7.3) | 6.3 (4.8, 8.3) | 9.3 (7.2, 12.1) | 10.8 (7.7, 15.0) |
| BNT162b2, n | 477 | 711 | 745 | 512 | 355 | 213 |
| % without RBD IgG | 7.1 (5.2, 9.9) | 9.4 (7.5, 11.8) | 10.6 (8.6, 13.1) | 15.0 (12.2, 18.5) | 23.7 (19.6, 28.5) | 32.9 (27.1, 39.8) |
| Ad26.COV2.S, n | 26 | 67 | 58 | 61 | 51 | - |
| % without RBD IgG | 77.0 (62.3, 94.9) | 50.7 (40.1, 64.2) | 44.8 (33.7, 59.6) | 52.5 (41.3, 66.6) | 56.9 (44.8, 72.2) | - |
| Positive | ||||||
| mRNA1273, n | 196 | 343 | 319 | 299 | 145 | 33 |
| % without RBD IgG | 1.5 (0.5, 4.7) | 1.7 (0.8, 3.9) | 2.2 (1.1, 4.6) | 3.3 (1.8, 6.2) | 5.5 (2.8, 10.8) | 12.1 (4.8, 30.4) |
| BNT162b2, n | 243 | 322 | 349 | 184 | 81 | 17 |
| % without RBD IgG | 4.5 (2.5, 8.1) | 5.0 (3.1, 8.0) | 6.6 (4.4, 9.8) | 9.8 (6.3, 15.2) | 14.8 (8.8, 25.0) | 17.6 (6.3, 49.3) |
| Ad26.COV2.S, n | 18 | 38 | 35 | 32 | 28 | - |
| % without RBD IgG | 66.7 (48.1, 92.4) | 52.6 (38.9, 71.2) | 48.6 (34.5, 68.3) | 53.1 (38.4, 73.6) | 57.1 (41.5, 78.8) | - |
|
| ||||||
| Overall % without RBD | 6.6 (5.5, 8.1) | 7.5 (6.5, 8.6) | 8.5 (7.4, 9.7) | 10.9 (9.6, 12.4) | 16.4 (14.5, 18.7) | 20.2 (17.1, 23.8) |
^
Includes lack of seroconversion on a total RBD assay or with RBD IgG index value below assay limit (<1). Data in parentheses represent 95% CI of the proportion without RBD IgG. Missing data are for time points with insufficient data.